Skip to main content
Division of Geriatrics, Gerontology & Palliative Care Division of Geriatrics, Gerontology & Palliative Care

schoolofmedlogo

WELCOME

Brain Health Update: Emerging Evidence for Shaping Better Care

December 3, 2026
7:45 AM - 1 PM
UC San Diego ACTRI Conference Room

Thank you for joining us for this annual event, which highlights the cutting-edge academic and scientific environment across the UCSD campus, and the strong relationships with major scientific institutes and broad range of medical and community partners in San Diego County working to advance knowledge and clinical practice in this field of study. This conference, hosted by the UC San Diego Shiley-Marcos Alzheimer’s Disease Research Center and the San Diego Alzheimer’s Disease Resource Center for Minority Aging Research (AD-RCMAR), brings together an internationally renowned faculty from UC San Diego and local partner institutions to present the latest developments in neurodegenerative research. We look forward to having you join us to learn more about the local landscape of this ever-evolving area of research and care.

Please check back in late October for more information and details on how to RSVP.

LEARNING OBJECTIVES

At the conclusion of this conference, participants should be able to:

  • Identify the multitude of factors that influence risk for ADRD in diverse patient populations, including the intersecting impacts of race, class, ethnicity, and sex.
  • Analyze the safety, efficacy, and expectations in using the anti-amyloid monoclonal antibodies (AAMAs) including Lecanemab (Leqembi™) and Donanemab (Kisunla™) as the first disease-modifying treatments for AD.
  • Recognize the multitude of comorbidities that influence rate of cognitive decline and quality of life in patients with ADRD.
  • Evaluate the proportion of risk of cognitive decline that is modifiable and introduce the possibility of reducing dementia risk and prevention through modifiable risk factors.
  • Assess the impact of lifestyle interventions related to diet, exercise, sleep, and stress reduction on persons already diagnosed with MCI and early AD, and consider the compounding impact possible with adjunctive therapies.
  • Analyze the move to a biologic definition of Alzheimer’s disease (AD), including the recently revised criteria for diagnosis and staging (Alzheimer's Association Workgroup).